Salestools LogoSalestools
Agenti IA Salestools
Soluzioni
Risorse
Azienda
Prezzi
Salestools Logo

Salestools

L'agente IA #1 per team di vendita e Go-to-Market. Vendi di più, più velocemente, con meno sforzo.

Prodotto

  • Agenti di vendita IA
  • Dati di intenzione
  • Dati Tecnologici
  • Tracciamento Visitatori
  • Co-Pilota
  • Vendita Sociale

Soluzioni

  • Servizio Clienti
  • E-commerce
  • SaaS
  • Impresa
  • Piccole Imprese

Risorse

  • Il rapporto
  • Documentazione
  • Riferimento API
  • Centro assistenza
  • Blog
  • Casi studio
  • Webinar

Azienda

  • Chi siamo
  • Carriere
  • Stampa
  • Contatto
  • Partner

Le nostre sedi

  • New York, HQ
  • Bucarest, Laboratorio di Ricerca IA
  • Zug, Svizzera

© 2026 Salestools. Tutti i diritti riservati.

Termini sui Dati e SicurezzaPolitica sulla privacyTermini di servizioAcceptable Use
Tutti i sistemi operativi
Salestools LogoSalestools
Agenti IA Salestools
Soluzioni
Risorse
Azienda
Prezzi
Back to Reports
Biotech

BioNTech

BioNTech raises $45B Public at $48B valuation

An der Goldgrube 12, Mainz 55131, GermanyJanuary 1, 20241 min read
Total Raised
$45B
Valuation
$48B
Latest Round
Public
Employees
5000+

BioNTech: Public Funding Round

BioNTech has successfully raised $45B in Public funding, reaching a valuation of $48B.

Company Overview

Biotechnology company

Funding Details

The Public round was led by Public.

Company Information

  • Headquarters: An der Goldgrube 12, Mainz 55131, Germany
  • Founded: 2008
  • Employees: 5000+
  • Category: Biotech

Investment

BioNTech plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

  • Public: Verified investor in Public

Company Info

Headquarters
An der Goldgrube 12, Mainz 55131, Germany
Founded
2008
Team Size
5000+
Last Round
$45B(Jan 2024)

Investors (1)

P
PublicLead
Lead Investor
Verified investor in Public

Topics

verified(3079)real-funding(3079)public(927)biontechbiotechan-der-goldgrube-12

Share

Related Reports

Biotech
AusperBio

AusperBio Raises $73M Series B

Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials

David Chen
David Chen
Dec 30, 2025
0 min read•$73M Series B
Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free